Lipid imbalance triggered by Snail-driven epithelial–mesenchymal transition creates a cholesterol-dependent vulnerability ...
A shift in the balance between two lipids – cholesterol and sphingomyelin – makes hybrid epithelial-mesenchymal cancer cells less responsive to certain chemotherapy drugs.
The FDA has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program. This is an expanded access program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback